...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: you won’t see anyone buying this

Thanks KK2. 36% dilution over the last 2 years alone. That means every royalty distribution will be more than 1/3 less forever. That's assuming we have salable drugs that hit the market.

tada 

 

Share
New Message
Please login to post a reply